• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

OpenAI-Backed Chai Discovery Raises $130M to Tackle “Undruggable” Targets with Generative AI

by Fred Pennic 12/15/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Chai Discovery has secured a $130M Series B financing round, propelling its valuation to $1.3 billion just months after emerging from stealth. 

– Co-led by Oak HC/FT and General Catalyst, the funding validates Chai’s proprietary AI models, which can predict biochemical interactions and design drugs for targets previously considered “undruggable.” 

– With backing from industry heavyweights like OpenAI and Thrive Capital, Chai is positioning itself to transform drug development from a slow, empirical art into a rapid, engineered discipline.

Chai Discovery Secures $1.3B Valuation to Rewrite Drug Development

For decades, drug discovery has been defined by a brutal metric: it takes over ten years and upwards of a billion dollars to bring a single medicine from the lab bench to the bedside. It is a process historically governed by trial, error, and luck. Today, Chai Discovery signaled that the era of “empirical art” in biology may be ending, and the era of “programmable biology” has begun.

The company announced a $130M Series B financing round today, placing its valuation at a staggering $1.3B. The round was co-led by Oak HC/FT and General Catalyst, with significant participation from OpenAI, Thrive Capital, and Menlo Ventures.

This capital injection comes on the heels of a $70M Series A just months ago, underscoring the voracious appetite investors have for Generative AI platforms that can demonstrate tangible, scientific utility beyond simple chatbots.

Solving “Five-Year Problems” in Weeks

The core of Chai’s value proposition lies in its ability to compress time. The company’s latest AI models are designed to predict and reprogram interactions between biochemical molecules—the fundamental building blocks of life.

According to Josh Meier, co-founder and CEO of Chai Discovery, the pace of innovation is accelerating faster than even industry insiders anticipated.

“We’re in awe of the rate of progress on the models – what looked like five-year problems just months ago are now getting solved in weeks,” Meier said. “Our latest models can design molecules that have properties we’d want from actual drugs, and tackle challenging targets that have been out of reach.”

This capability was highlighted by the recent reveal of Chai 2, a zero-shot generative platform. The company claims this model achieves double-digit experimental success rates in de novo antibody design—a statistic representing a 100-fold improvement over previous computational methods.

Moving Beyond “Undruggable”

The pharmaceutical industry is littered with “undruggable” targets—biological pathways known to cause disease but which, due to their chemical structure, cannot be bound by traditional small molecules or biologics.

Chai’s platform focuses on “developability.” It’s not enough to design a molecule that works in a computer simulation; it must work in the human body. Chai’s models are optimizing for these real-world properties, converting a lengthy physical iteration cycle into a rapid computational process. This allows them to tackle those historically difficult targets and materially compress the timeline to first-in-human studies.

A Heavy-Hitting Board for a New Era

The financing also reshapes Chai’s governance. Annie Lamont, Co-Founder & Managing Partner at Oak HC/FT, and Hemant Taneja, CEO of General Catalyst, will join Chai’s board of directors.

“Nowhere is AI transformation more needed than in drug development – the process is slow, expensive, and imprecise,” said Lamont. “The Chai Discovery team is rewriting that story, fusing world-class AI and biological expertise to dramatically accelerate how medicines are discovered.”

With total funding now exceeding $225M, Chai plans to use the fresh capital to accelerate its research and product development. The goal is to build what the company describes as a “computer-aided design suite” for molecules—software that could eventually become the standard operating system for the biopharmaceutical industry.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |